Search Results
Jun 24, 2025, 09:00 ET CivicaScript® Launches Low-Cost Multiple Sclerosis Treatment to Increase Patient Access, Create Significant Savings
our journey to make necessary medications more affordable for the patients who need them," said CivicaScript President Brent J. Eberle. "We're bringing transparency and affordability to the generic drug market in a sustainable way – saving money for patients and payers
More news about: CivicaScript
Jun 24, 2025, 08:33 ET Spanish Language Sessions Return to Equip Expo by Popular Demand
https://www.dropbox.com/scl/fo/05ir6sobsdl9ev7jaen2i/ACEWUvJL92GEnbBpyNccGg0?rlkey=09qbcbdazooluvdius4j2jbk6&dl=0 Embeddable Video:
More news about: Equip Exposition
Jun 24, 2025, 08:15 ET Children's Hospital of Philadelphia and St. Jude Researchers Find Genetic Ancestry Influences How Gene Mutations Impact Cancer Prognosis in Patients With T-cell Acute Lymphoblastic Leukemia
Jun J. Yang, PhD, Endowed Chair in Pharmacogenomics of the St. Jude Department of Pharmacy and Pharmaceutical Sciences. "The lessons learned
More news about: Children's Hospital of Philadelphia
Jun 24, 2025, 08:01 ET Stuart Therapeutics Announces Initial Results of Phase III Clinical Trial for ST-100 (Vezocolmitide) Ophthalmic Solution, a Novel Dry Eye Disease Candidate
Calkins, D.J. Intraocular Delivery of a Collagen Mimetic Peptide Repairs Retinal Ganglion Cell Axons in Chronic and Acute Injury Models (2022). Int. J. Mol. Sci. 23:2911,
More news about: Stuart Therapeutics
Jun 24, 2025, 08:00 ET VANCORD NAMED TO 2025 CHANNEL PARTNERS MSP 501 LIST OF TOP GLOBAL MANAGED SERVICE PROVIDERS
501 is a powerful validation of the strategic investments we've made in people, process, and technology," said Michael J. Grande, CEO of
More news about: Vancord
Jun 24, 2025, 08:00 ET Kasowitz LLP and Mishcon de Reya LLP, on behalf of Erion Veliaj, Mayor of Tirana, Publish Report Regarding SPAK's Unjust Detention of a Democratically Elected Mayor
[email protected]. The Kasowitz team includes partners Daniel J. Fetterman, Brian S. Choi, and Joshua E. Roberts in New
More news about: Kasowitz LLP
Jun 24, 2025, 08:00 ET Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH
Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284-291. doi: 10.1016/j.jhep.2021.02.034.3. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss
More news about: Rivus Pharmaceuticals
Jun 24, 2025, 07:55 ET Thrive Scholars Expands 2025 Summer Academies Across Five Cities with Largest Cohort Yet
my dream school, UCLA!" "Thrive had a significant impact on my academic confidence and future goals," said Evelin J., a second-year Thrive Academies Scholar and rising college first-year at University of California, Irvine. "Thrive Academy
More news about: Thrive Scholars
Jun 24, 2025, 07:00 ET Cristcot Highlights Engagement with GI Community at 2025 GI ReConnect Annual Meeting
esteemed colleagues and thought leaders in gastroenterology on our efforts in addressing the needs of UC patients," said Jennifer J. Davagian, Founder and Chief Executive Officer, Cristcot. "Currently the Company is in a period of immense momentum as we work to advance our late-stage
More news about: Cristcot
Jun 24, 2025, 07:00 ET CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
X U.S. Company Contact: Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ 08540
More news about: Cytosorbents Corp
Jun 24, 2025, 07:00 ET Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease
and regulatory aspects of clinical development of novel therapies. Byron L. Lam, MD, is Professor and Mark J. Daily Chair of Ophthalmology at the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute. A leading
More news about: Ascidian Therapeutics
Jun 24, 2025, 06:02 ET 全新SKINVIVE® 昇光針® 矚目登場 -- 引領突破水光界限
References: 1. Ogilvie P et al. J Cosmet Dermatol. 2020;19(5):1065–1070 2. Clin Cosmet Investig Dermatol. 2022 Mar 10;15:411–426
More news about: Allergan Aesthetics
Jun 24, 2025, 05:29 ET Accord Healthcare recibe la aprobación para Hetronifly® de la MHRA para el tratamiento de ES-SCLC
Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834MHRA aprueba el primer anticuerpo monoclonal anti-PD-1 de Reino Unido para el tratamiento de
More news about: Accord Healthcare
Jun 24, 2025, 04:00 ET Jacobs and AtkinsRéalis Appointed National Highways' Environmental and Sustainability Technical Partner
Jacobs (NYSE: J), in joint venture with
More news about: Jacobs
Jun 24, 2025, 03:49 ET NSSC Shareholders Have the Right to Lead the Napco Security Technologies, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - NSSC
Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email:
More news about: DJS Law Group LLP
Jun 24, 2025, 03:43 ET Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN
Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone:
More news about: DJS Law Group LLP
Jun 24, 2025, 02:30 ET Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
DP, Auchus RJ. N Engl J Med 2020;383(13):1248-61 Claahsen-van der Grinten HL, et al. Endocr Rev 2022;43(1):91-159 Lundbeck. Data on file Feldhaus AL, et al. Endocrinology 2017;158(1):1-8 Xing Y, et al. J Endocrinol 2011;209(3):327-35
More news about: H. Lundbeck A/S
Jun 24, 2025, 02:23 ET Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
DP, Auchus RJ. N Engl J Med 2020;383(13):1248-61 Claahsen-van der Grinten HL, et al. Endocr Rev 2022;43(1):91-159 Lundbeck. Data on file Feldhaus AL, et al. Endocrinology 2017;158(1):1-8 Xing Y, et al. J Endocrinol 2011;209(3):327-35
More news about: H. Lundbeck A/S
Jun 24, 2025, 02:16 ET Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval
Gastroenterol. 2013 Jun;27(3):401-14. doi: 10.1016/j.bpg.2013.06.005. PMID: 23998978; PMCID: PMC3761380. Harsányi, L., Kincses, Z., Zehetner, J. et al. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective
More news about: Implantica
Jun 24, 2025, 02:00 ET Accord Healthcare receives approval for Hetronifly® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834MHRA approves the UK's first anti-PD-1 monoclonal antibody for the treatment of an aggressive
More news about: Accord Healthcare
Jun 24, 2025, 02:00 ET Accord Healthcare erhält die Zulassung für Hetronifly® (Serplulimab) von der Medicines and Healthcare Regulatory Agency (MHRA) für die Erstlinienbehandlung von kleinzelligem Lungenkrebs im Extensivstadium (ES-SCLC)
Laversanne M, Sung H, et al. Weltweite Krebsstatistik 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 2. MHRA genehmigt den ersten monoklonalen Anti-PD-1-Antikörper in Großbritannien zur Behandlung
More news about: Accord Healthcare
Jun 24, 2025, 02:00 ET Accord Healthcare reçoit l'approbation de la Medicines and Healthcare Regulatory Agency (MHRA) pour Hetronifly® (Serplulimab), pour le traitement de première ligne du cancer du poumon à petites cellules au stade extensif (ES-SCLC).
Statistiques mondiales sur le cancer 2022 : Estimations GLOBOCAN de l'incidence et de la mortalité dans le monde pour 36 cancers dans 185 pays. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 2. La MHRA approuve le premier anticorps monoclonal anti-PD-1 du Royaume-Uni pour le traitement
More news about: Accord Healthcare
Jun 23, 2025, 23:55 ET Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone:
More news about: DJS Law Group LLP
Jun 23, 2025, 17:38 ET Red Rock Resorts Announces Date of Second Quarter 2025 Conference Call and Earnings Release Date
Investors:Red Rock ResortsStephen L. Cootey(702) 495-3550 Media:Michael J. Britt(702) [email protected]
More news about: Red Rock Resorts, Inc.
Jun 23, 2025, 16:23 ET MedStar Washington Hospital Center Earns Prestigious Magnet Recognition for Nursing
Gregory J. Argyros, MD, president, MedStar Washington Hospital Center. "These rare badges of honor not only help us attract and retain top nursing talent,
More news about: MedStar Washington Hospital Center